Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
A lot of good things said, great communication and delivery.
- very positive safety data, well tolerated, significant reduction in toxicities being experienced, released at levels required to have therapeutic effect (January update).
- will keep market updated on any cohort. No news means we are getting on with it!
- P1b and 2 may be enough for approval (8:28 "at least").
- better quality of life.
- 3996 poster update will also contain 6000 info.
- 3996 sounding like it puts the incredible 6000 to shame. Tumor agnostic? (long way to go but encouraging so far).
- Lots of smiling, looking relaxed (resulting in the best thumbnail of AVCT to date).
Calm about having added significantly over past few sessions.
GLA
Ray
https://www.voxmarkets.co.uk/articles/q-a-with-avacta-s-ceo-alastair-smith-e87d9e8/
Someone looks quite happy.
This seems like a human error somewhere (possibly by the PR company or whoever is in charge of submitting + publishing these. Zyme? Yellow PR?), it looks and reads like an RNS and it somehow made it into one of the channels. Wouldn't be surprised if they rectified this soon.
Regardless, good news.
Is it possible that with the end of the tax year approaching, investors want to take advantage of the last CGT 12.3k allowance? Anybody who’s put in money in the last 12 months should be up a fair amount! Science day was great but they could have communicated it better or hyped it up more, that‘s for sure. If you didn‘t watch the video, one could believe that no progress is being made which is categorically false. Clearly the twitter and boards are flooded with paid trolls, because why else would anybody spend hours per day wasting their time on deramping stocks? The SP rose in anticipation and people took profits. Well done. Now the news cycle will start again, the TAers will go from bear to bull (or maybe not, see what I did there? No matter what, they are always right.). We‘ve seen many ups and downs. Ignore the day to day or week to week movements, if you‘re a “LTH“. AVA6000 trial is promising, no denying that. 3996 also. Many more in the pipeline, TMAC, Affimers, Affyxell, Diagnostics etc. I am sleeping well at night, despite the occasional massive gains and losses when I check the SP on a day to day basis.
it said 0.50% 21 January 2022, well over a year ago. Many more shares have been added since, so why would it only update now? Their short opened in Dec 21, if the trackers are to be trusted.
Anyway,
SP since 21 Jan 2022: roughly +75%. (huge loss? )
SP since 6 Dec 2021: roughly +13%. (decent loss?)
Well done BC!
The next RNS should be an update on the trial (new DE / P1b) or AACR AVA3996 poster. LTHs will remember the last AACR was at the base of a big SP rerate. We have been told 3996 data has been accepted so we can all but guarantee an RNS about it this month?
iydrc:
29th Mar 2022
RNS AVA6000 data poster presentation at AACR
———— > ?
28th March 2023
RNS AVA3996 data poster presentation at AACR
No idea when or if we should be expecting news on Affyxell diagnostic progress, or any other projects but I would not be surprised if we do.
GLA LTH
Ray
mentioned
-science day in a couple weeks, implying would be held there
- have a P1 trial ongoing in 6 UK hospitals including Marsden (Imperial)
-importance of academic collaborations. Unis want funding and publishing, whereas they as a company want data so the new location is great for them
-at the site for about a year. places like white city campus ideal to accelerate science, which is of main importance to companies like them on tight time scales (patents)
the event is to highlight/advertise the university environment as a catalyst for UK science and collaborations. a lot of praise about the location, space to grow, etc.
doubtful that they would be mentioning these short term things if they were about to be duds. being invited and talking at such events very positive
Spotted at JP morgan day four highlights
https://scrip.pharmaintelligence.informa.com/SC147642/JP-Morgan-Day-Four-Talking-With-Execs-About-BD-Plans
Takeda Focused On Early Collaborations, Single-Asset Deals
Takeda Pharmaceutical Co. Ltd. president of research and development Andy Plump described the company’s business development intentions for Scrip in an interview at J.P. Morgan, noting that the strategy starts with a focus on four core therapeutic areas – gastrointestinal diseases, oncology, neuroscience and a broader category that includes rare and genetic diseases and hematology.
“Secondly, as we have for the past eight years, we continue to be very proactive in early-stage research, platform-based partnerships – that's fundamental to our innovation model,” Plump said. “We've fully bought into the fact that we have really great labs, but even with our great labs, the majority of what we'll eventually bring to patients will come through our partners and that's what the industry has taught us over decades and decades.”
He noted that partnering earlier in the research and development process brings a less expensive upfront cost than a later-stage collaboration, but also “they help our own scientists evolve and grow. And we're starting to see success from that strategy now and we continue to do that.”
In addition, Takeda is interested in targeted asset acquisitions or licensing deals across its four core therapeutic areas, such as the deal it announced in December with Nimbus Therapeutics, Inc. to acquire the Phase III-ready TYK2 inhibitor NDI034858 for $4bn up front. (Also see "Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor" - Scrip, 13 Dec, 2022.) Plump also pointed to Takeda’s collaboration announced in October with Dr. Falk Pharma GmbH for TAK-227, a transglutaminase 2 inhibitor in Phase IIb for celiac disease, as a recent example of the single-asset part of the company’s business development strategy. (Also see "Asia Deal Watch: Astellas Invests In Taysha, Gets Rights To Two AAV Gene Therapies" - Scrip, 25 Oct, 2022.)
“We don't emphasize one [type of deal] over the other,” he said. “We're looking for the best opportunities. It's quite hard to find really compelling assets in late stage and when you do, like the Nimbus program, they are very competitive. There just aren't that many out there.”
CEO said it would be absolutely inappropriate to talk about the ongoing trial (phase) when Paul Hill tried to ask about it. I expect this still to be the case and therefore P1a to have been completed and they are gearing up towards P1b and can talk about P1a. P1a results are being processed, written up, passing some kind of data/ethical approval. Obviously the result RNS won’t be the day the trial ends. There will be a bit of buffer. To me, the last RNS was signalling the end of P1a. Happy to be wrong.